IN2012DN02469A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02469A
IN2012DN02469A IN2469DEN2012A IN2012DN02469A IN 2012DN02469 A IN2012DN02469 A IN 2012DN02469A IN 2469DEN2012 A IN2469DEN2012 A IN 2469DEN2012A IN 2012DN02469 A IN2012DN02469 A IN 2012DN02469A
Authority
IN
India
Application number
Inventor
Shenlin Huang
Xianming Jin
Zuosheng Liu
Daniel Poon
John E Tellew
Yongqin Wan
Xing Wang
Yongping Xie
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US23807309P priority Critical
Priority to US31303910P priority
Priority to PCT/US2010/046930 priority patent/WO2011025927A1/en
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of IN2012DN02469A publication Critical patent/IN2012DN02469A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
IN2469DEN2012 2009-08-28 2012-03-21 IN2012DN02469A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US23807309P true 2009-08-28 2009-08-28
US31303910P true 2010-03-11 2010-03-11
PCT/US2010/046930 WO2011025927A1 (en) 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN02469A true IN2012DN02469A (en) 2015-08-21

Family

ID=42782253

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2469DEN2012 IN2012DN02469A (en) 2009-08-28 2012-03-21

Country Status (44)

Country Link
US (9) US8501758B2 (en)
EP (2) EP2727918B1 (en)
JP (2) JP5475888B2 (en)
KR (1) KR101413392B1 (en)
CN (2) CN103896921B (en)
AR (1) AR077975A1 (en)
AU (1) AU2010286569C1 (en)
CA (1) CA2771775C (en)
CO (1) CO6612222A2 (en)
CR (1) CR20120102A (en)
CU (1) CU24110B1 (en)
CY (1) CY1118452T1 (en)
DK (2) DK2470526T3 (en)
DO (1) DOP2012000051A (en)
EA (2) EA025222B1 (en)
EC (1) ECSP12011700A (en)
ES (2) ES2610825T3 (en)
GT (1) GT201200053A (en)
HK (1) HK1167390A1 (en)
HN (1) HN2012000441A (en)
HR (2) HRP20140799T1 (en)
HU (3) HUE032847T2 (en)
IL (1) IL218084A (en)
IN (1) IN2012DN02469A (en)
JO (1) JO3002B1 (en)
LT (3) LT2727918T (en)
MA (1) MA33604B1 (en)
ME (2) ME01860B (en)
MX (1) MX2012002546A (en)
MY (1) MY156259A (en)
NO (2) NO2019012I1 (en)
NZ (1) NZ598924A (en)
PE (1) PE20120861A1 (en)
PL (2) PL2727918T3 (en)
PT (2) PT2470526E (en)
RS (2) RS53489B1 (en)
SG (2) SG178351A1 (en)
SI (2) SI2470526T1 (en)
SM (2) SMT201400133B (en)
TN (1) TN2012000081A1 (en)
UA (1) UA112285C2 (en)
UY (1) UY32860A (en)
WO (1) WO2011025927A1 (en)
ZA (1) ZA201202020B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
KR101814223B1 (en) 2010-02-25 2018-01-02 다나-파버 캔서 인스티튜트 인크. Braf mutations conferring resistance to braf inhibitors
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
CN103917236A (en) * 2011-11-11 2014-07-09 诺华股份有限公司 Method of treating proliferative disease
CN105708819A (en) * 2011-11-23 2016-06-29 诺华股份有限公司 Pharmaceutical formulations
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (en) * 2011-12-10 2015-05-13 通化济达医药有限公司 Substitutional pyrazol kinase inhibitor
US20130165483A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP6348898B2 (en) 2012-03-28 2018-06-27 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド C-RAF mutants that confer resistance to RAF inhibitors
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
MX2015000794A (en) 2012-07-18 2015-10-12 Univ Saint Louis Beta amino acid derivatives as integrin antagonists.
AR091876A1 (en) * 2012-07-26 2015-03-04 Novartis Ag pharmaceutical combinations for the treatment of proliferative diseases
CA2879548A1 (en) 2012-08-07 2014-02-13 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2014047330A1 (en) * 2012-09-19 2014-03-27 Jean-Michel Vernier Novel raf kinase inhibitors
AU2013343425A1 (en) * 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
EA201591842A1 (en) 2013-03-21 2016-01-29 Новартис Аг Combined therapy
TWI634114B (en) * 2013-05-08 2018-09-01 永恒生物科技公司 Furanone compounds as kinase inhibitors
RU2015149937A (en) * 2013-05-30 2017-07-06 Плексксикон Инк. Compounds for kinase modulation and indications for their application
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
CN106211755A (en) * 2013-12-20 2016-12-07 生物医学谷探索股份有限公司 Use the treatment of cancer of the combination of ERK and RAF inhibitor
MX2016008362A (en) * 2013-12-23 2016-09-08 Novartis Ag Pharmaceutical combinations.
LT3097121T (en) 2014-01-24 2019-05-10 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
EA201691556A1 (en) 2014-01-31 2016-12-30 Новартис Аг Antibody molecules for tim-3 and their application
DE102015103158A1 (en) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Compounds for the treatment of melanoma
AU2015229103A1 (en) 2014-03-14 2016-08-04 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3143166A4 (en) 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
CN107074828A (en) * 2014-09-12 2017-08-18 诺华股份有限公司 Compound and composition as RAF kinase inhibitors
BR112017004826A2 (en) 2014-09-13 2017-12-12 Novartis Ag alk inhibitor combination therapies
JP2017535528A (en) 2014-10-03 2017-11-30 ノバルティス アーゲー Combination therapy
EA201790799A1 (en) 2014-10-08 2017-08-31 Новартис Аг Compositions and methods for use to strengthen immune response and therapy of malignant tumors
KR20170069257A (en) 2014-10-14 2017-06-20 노파르티스 아게 Antibody molecules to pd-l1 and uses thereof
MX2017011597A (en) 2015-03-10 2018-05-11 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling.
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
JP2019500355A (en) 2015-12-30 2019-01-10 セントルイス ユニバーシティ Meta-azacyclic aminobenzoic acid derivatives as pan-integrin antagonists
RU2615986C1 (en) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Substituted methyl(2-{4-[3-(3-methanesulfonylamino-2-fluoro-5-chloro-phenyl)-1h-pyrazol-4-yl]pyrimidin-2-ylamino}ethyl) carbamates, process for their preparation and application
AU2017275650A1 (en) 2016-06-03 2019-01-17 Array Biopharma Inc. Pharmaceutical combinations
EP3564232A1 (en) 2016-12-27 2019-11-06 Riken Bmp-signal-inhibiting compound
US20190365920A1 (en) 2017-02-10 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
UY37695A (en) 2017-04-28 2018-11-30 Novartis Ag Bis cyclic compound dinucleotide 2'-5'-r-- (3'fa) (3'fa) and uses thereof
CN107540699A (en) * 2017-10-16 2018-01-05 康化(上海)新药研发有限公司 A kind of synthetic method of the boric acid hydrochloride of 2 amino, 3 fluorine pyridine 4
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
DE3571974D1 (en) 1984-12-06 1989-09-07 Pfizer Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0910401A1 (en) 1996-05-23 1999-04-28 Applied Research Systems ARS Holding N.V. Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc Quinazoline-based compound, famaceutica composition comprising it, to synthesize method, use, methods of modulating the function deserina / threonine protein kinase with said compound and in vitro method for identifying compounds that modulate said function
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AP1246A (en) 1997-05-22 2004-02-07 Searle & Co Substituted pyrazoles as p38 Kinase inhibitors.
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (en) 1999-01-13 2008-08-20 Байер Копэрейшн Derivatives of urea (variants), pharmaceutical composition (variants) and method for treatment of diseases associated with cancer cells growth (variants)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
AU8534901A (en) 2000-08-30 2002-03-13 Univ Arkansas Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag Hydroxamate compounds as inhibitors of histone deacetylase (HDA)
US7247734B2 (en) 2001-12-21 2007-07-24 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
MXPA06003163A (en) 2003-09-23 2006-06-05 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent.
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
CN1906188A (en) 2004-01-09 2007-01-31 诺瓦提斯公司 Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-1R inhibitors
CN1960988B (en) 2004-06-10 2012-01-25 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
JP5178515B2 (en) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Pyrazole compounds that modulate Hsp90 activity
US20090214645A1 (en) 2005-08-22 2009-08-27 Andrea Kramer Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
TWI387592B (en) 2005-08-30 2013-03-01 Novartis Ag Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis
JP2009530261A (en) * 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク Pyrazole compounds
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN101522026A (en) * 2006-10-06 2009-09-02 Irm责任有限公司 Protein kinase inhibitors and methods for using thereof
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
EP2183243A2 (en) * 2007-08-01 2010-05-12 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
EP2197425A2 (en) 2007-10-19 2010-06-23 Abbott GmbH & Co. KG Solid dispersion product of n-aryl urea-based drugs
CN101861316B (en) * 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
MX2010010317A (en) * 2008-03-21 2010-10-04 Novartis Ag Novel heterocyclic compounds and uses therof.
HUE028820T2 (en) * 2008-05-06 2017-01-30 Novartis Ag Benzene sulfonamide thiazole and oxazole compounds
PT2324008E (en) * 2008-07-24 2012-06-25 Nerviano Medical Sciences Srl 3,4-diarylpyrazoles as protein kinase inhibitors
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
CA2738448A1 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
PL2346495T3 (en) 2008-10-07 2017-02-28 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010056662A1 (en) * 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (en) 2009-01-29 2011-03-16 Novartis Ag Oral formulations a solid pyrido-pyrimidinone
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (en) 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
ES2679379T3 (en) * 2009-06-15 2018-08-24 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and use as kinase inhibitors
KR101256018B1 (en) * 2009-08-20 2013-04-18 한국과학기술연구원 1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EP2528909B1 (en) 2010-01-27 2016-06-22 Nerviano Medical Sciences S.r.l. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
CN104940200B (en) 2010-03-30 2019-06-28 维颂公司 Inhibitor of the polysubstituted aromatic compounds as fibrin ferment
JP5938038B2 (en) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ Derivatives of pyrazolophenyl-benzenesulfonamide compounds and their use as antitumor agents
JP5999724B2 (en) 2011-03-21 2016-09-28 ヴァルキュリア アクチアボラグValcuria AB Pharmaceutical composition comprising an HDAC inhibitor and a steroid and use thereof
KR20140056212A (en) 2011-06-14 2014-05-09 노파르티스 아게 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
CN105708819A (en) 2011-11-23 2016-06-29 诺华股份有限公司 Pharmaceutical formulations
AU2013343425A1 (en) 2012-11-08 2015-06-11 Novartis Ag Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases

Also Published As

Publication number Publication date
NO2019012I1 (en) 2019-03-05
MX2012002546A (en) 2012-04-11
IL218084A (en) 2016-11-30
US20160280687A1 (en) 2016-09-29
US9850229B2 (en) 2017-12-26
PT2470526E (en) 2014-09-01
CN102725283B (en) 2014-02-26
WO2011025927A1 (en) 2011-03-03
KR20120062839A (en) 2012-06-14
CA2771775A1 (en) 2011-03-03
EP2727918A1 (en) 2014-05-07
HUE032847T2 (en) 2017-11-28
LTPA2019005I1 (en) 2019-03-25
HUS1900013I1 (en) 2019-04-29
HN2012000441A (en) 2015-01-05
KR101413392B1 (en) 2014-06-27
GT201200053A (en) 2014-03-27
US20110306625A1 (en) 2011-12-15
SI2727918T1 (en) 2017-02-28
AU2010286569C1 (en) 2019-11-28
IL218084D0 (en) 2012-04-30
ME02684B (en) 2017-06-20
CR20120102A (en) 2012-05-02
EP2470526A1 (en) 2012-07-04
DK2470526T3 (en) 2014-08-25
RS53489B1 (en) 2015-02-27
LTPA2019006I1 (en) 2019-03-25
SMT201700036B (en) 2017-03-08
TN2012000081A1 (en) 2013-09-19
SG178351A1 (en) 2012-03-29
EA025222B1 (en) 2016-12-30
JP2013503186A (en) 2013-01-31
EA201500175A1 (en) 2015-05-29
US20160280686A1 (en) 2016-09-29
CU20120034A7 (en) 2012-06-21
ZA201202020B (en) 2012-12-27
US20160120866A1 (en) 2016-05-05
CO6612222A2 (en) 2013-02-01
US20160263113A1 (en) 2016-09-15
SMT201400133B (en) 2014-11-10
US9850230B2 (en) 2017-12-26
MA33604B1 (en) 2012-09-01
AU2010286569B2 (en) 2013-10-10
SG10201405311TA (en) 2014-09-26
PE20120861A1 (en) 2012-07-14
CU24110B1 (en) 2015-07-30
US20130296318A1 (en) 2013-11-07
EP2470526B1 (en) 2014-05-28
HRP20140799T1 (en) 2014-11-07
CA2771775C (en) 2015-01-20
US20160122324A1 (en) 2016-05-05
HK1167390A1 (en) 2014-12-12
ES2492499T3 (en) 2014-09-09
RS55568B1 (en) 2017-05-31
MY156259A (en) 2016-01-29
JP2014098022A (en) 2014-05-29
EA201200373A1 (en) 2012-09-28
DOP2012000051A (en) 2012-05-31
ME01860B (en) 2014-12-20
US8501758B2 (en) 2013-08-06
UA112285C2 (en) 2016-08-25
UY32860A (en) 2011-03-31
PL2727918T3 (en) 2017-06-30
AU2010286569A1 (en) 2012-04-12
ES2610825T3 (en) 2017-05-03
JP6045519B2 (en) 2016-12-14
US9314464B2 (en) 2016-04-19
CY1118452T1 (en) 2017-07-12
LT2727918T (en) 2017-01-25
NO2019011I1 (en) 2019-03-05
US10005761B2 (en) 2018-06-26
HRP20170005T1 (en) 2017-03-10
PT2727918T (en) 2017-01-20
ECSP12011700A (en) 2012-03-30
US9593100B2 (en) 2017-03-14
CN103896921B (en) 2016-02-24
JP5475888B2 (en) 2014-04-16
US20180297986A1 (en) 2018-10-18
CN103896921A (en) 2014-07-02
DK2727918T3 (en) 2017-01-23
NZ598924A (en) 2013-07-26
AR077975A1 (en) 2011-10-05
US20180297985A1 (en) 2018-10-18
PL2470526T3 (en) 2014-10-31
US9593099B2 (en) 2017-03-14
JO3002B1 (en) 2016-09-05
SI2470526T1 (en) 2014-09-30
EP2727918B1 (en) 2016-10-12
CN102725283A (en) 2012-10-10
HUS1900012I1 (en) 2019-04-29

Similar Documents

Publication Publication Date Title
IN2009KO00877A (en)
IN2011KN05199A (en)
IN2012DN00350A (en)
IN2011KN03766A (en)
IN2012DN00695A (en)
IN2009DE00085A (en)
IN2012DN00387A (en)
IN2012DN00588A (en)
IN2012DN00314A (en)
IN2012DN00547A (en)
CN101593473K1 (en)
IN2012DN00649A (en)
IN2010KN02118A (en)
IN2012DN00370A (en)
CN101594669K1 (en)
IN2012DN00445A (en)
CN102088494K1 (en)
IN2012DN00303A (en)
CN101674240K1 (en)
IN2012DN00526A (en)
IN2012DN00517A (en)
IN2012DN00216A (en)
IN2012DN00568A (en)
IN2009DE01802A (en)
ECSDI099540S (en)